Josh is co-founder and chief executive officer of Ataxion, and previously served on the board of CoStim Pharmaceuticals, which was sold to Novartis in February 2014. He is also an attending physician in emergency medicine at Brigham and Women's Hospital as well as an instructor at Harvard Medical School. Prior to joining Atlas, Josh was a partner at Prism Ventures.